• Something wrong with this record ?

Optimizing the safety and efficacy of the awake venovenous extracorporeal membrane oxygenation in patients with COVID-19-related ARDS

P. Sklienka, F. Burša, M. Frelich, J. Máca, V. Vodička, H. Straková, M. Bílená, T. Romanová, H. Tomášková

. 2024 ; 18 (-) : 17534666241282590. [pub] -

Language English Country England, Great Britain

Document type Journal Article

Persistent link   https://www.medvik.cz/link/bmc25004193

BACKGROUND: Maintaining the patient awake and not intubated during the venovenous extracorporeal membrane oxygenation (VV ECMO) reduces the risk of ventilation-induced lung injury in patients with ARDS. Currently, there is a lack of data on outcomes and complications associated with the awake ECMO approach. OBJECTIVES: To evaluate outcomes and the occurrence of complications of awake ECMO approach guided by local safety protocol comprising ultrasound-guided cannulation, argatroban-based anticoagulation, respiratory support, and routine sedation targeted to reduce respiratory effort and keeping nurse-to-patient ratio of 1:1. DESIGN: A single-center retrospective case series analysis. METHODS: Consecutive patients with COVID-19-related acute respiratory distress syndrome (ARDS) (CARDS) treated by full awake VV ECMO approach from April 2019 to December 2023 were eligible. RESULTS: Our center treated 10 patients (mean age 54.7 ± 11.6 years) with CARDS with an awake ECMO approach. The reasons for awake ECMO included the presence of barotrauma in six patients, a team consensus to prefer awake ECMO instead of mechanical ventilation in three patients, and the patient's refusal to be intubated in one case. Before ECMO, patients were severely hypoxemic, with a mean value of Horowitz index of 48.9 ± 9.1 mmHg and a mean respiratory rate of 28.8 ± 7.3 breaths per minute on high-flow nasal cannula or noninvasive ventilation support. The mean duration of awake VV ECMO was 558.0 ± 173.6 h. Seven patients (70%) were successfully disconnected from ECMO and fully recovered. Intubation from respiratory causes was needed in three patients (30%), all of whom died eventually. In total, three episodes of delirium, two episodes of significant bleeding, one pneumothorax requiring chest tube insertion, and one oxygenator acute exchange occurred throughout the 5580 h of awake ECMO. No complications related to cannula displacement or malposition occurred. CONCLUSION: The awake ECMO strategy guided by safety protocol appears to be a safe approach in conscious, severely hypoxemic, non-intubated patients with COVID-19-related ARDS.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc25004193
003      
CZ-PrNML
005      
20250206110007.0
007      
ta
008      
250121s2024 enk f 000 0|eng||
009      
AR
024    7_
$a 10.1177/17534666241282590 $2 doi
035    __
$a (PubMed)39418135
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a enk
100    1_
$a Sklienka, Peter $u Department of Anesthesiology and Intensive Care Medicine, University Hospital of Ostrava, 17. listopadu 1790, Ostrava 70800, Czech Republic $u Department of Anesthesiology and Intensive Care Medicine, Faculty of Medicine, University of Ostrava, Syllabova 19, Ostrava 70300, Czech Republic $u Institute of Physiology and Pathophysiology, Faculty of Medicine, University of Ostrava, Syllabova 19, Ostrava70300, Czech Republic $1 https://orcid.org/0000000203305323 $7 xx0107715
245    10
$a Optimizing the safety and efficacy of the awake venovenous extracorporeal membrane oxygenation in patients with COVID-19-related ARDS / $c P. Sklienka, F. Burša, M. Frelich, J. Máca, V. Vodička, H. Straková, M. Bílená, T. Romanová, H. Tomášková
520    9_
$a BACKGROUND: Maintaining the patient awake and not intubated during the venovenous extracorporeal membrane oxygenation (VV ECMO) reduces the risk of ventilation-induced lung injury in patients with ARDS. Currently, there is a lack of data on outcomes and complications associated with the awake ECMO approach. OBJECTIVES: To evaluate outcomes and the occurrence of complications of awake ECMO approach guided by local safety protocol comprising ultrasound-guided cannulation, argatroban-based anticoagulation, respiratory support, and routine sedation targeted to reduce respiratory effort and keeping nurse-to-patient ratio of 1:1. DESIGN: A single-center retrospective case series analysis. METHODS: Consecutive patients with COVID-19-related acute respiratory distress syndrome (ARDS) (CARDS) treated by full awake VV ECMO approach from April 2019 to December 2023 were eligible. RESULTS: Our center treated 10 patients (mean age 54.7 ± 11.6 years) with CARDS with an awake ECMO approach. The reasons for awake ECMO included the presence of barotrauma in six patients, a team consensus to prefer awake ECMO instead of mechanical ventilation in three patients, and the patient's refusal to be intubated in one case. Before ECMO, patients were severely hypoxemic, with a mean value of Horowitz index of 48.9 ± 9.1 mmHg and a mean respiratory rate of 28.8 ± 7.3 breaths per minute on high-flow nasal cannula or noninvasive ventilation support. The mean duration of awake VV ECMO was 558.0 ± 173.6 h. Seven patients (70%) were successfully disconnected from ECMO and fully recovered. Intubation from respiratory causes was needed in three patients (30%), all of whom died eventually. In total, three episodes of delirium, two episodes of significant bleeding, one pneumothorax requiring chest tube insertion, and one oxygenator acute exchange occurred throughout the 5580 h of awake ECMO. No complications related to cannula displacement or malposition occurred. CONCLUSION: The awake ECMO strategy guided by safety protocol appears to be a safe approach in conscious, severely hypoxemic, non-intubated patients with COVID-19-related ARDS.
650    _2
$a lidé $7 D006801
650    12
$a mimotělní membránová oxygenace $x škodlivé účinky $x metody $7 D015199
650    _2
$a lidé středního věku $7 D008875
650    _2
$a retrospektivní studie $7 D012189
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a ženské pohlaví $7 D005260
650    12
$a COVID-19 $x komplikace $x terapie $7 D000086382
650    12
$a syndrom dechové tísně $x terapie $x etiologie $7 D012128
650    _2
$a dospělí $7 D000328
650    _2
$a senioři $7 D000368
650    12
$a bdění $7 D014851
650    _2
$a výsledek terapie $7 D016896
650    _2
$a antikoagulancia $x aplikace a dávkování $x škodlivé účinky $x terapeutické užití $7 D000925
650    _2
$a intervenční ultrasonografie $7 D018084
650    _2
$a arginin $x analogy a deriváty $7 D001120
650    _2
$a kyseliny pipekolové $7 D010875
650    _2
$a sulfonamidy $7 D013449
655    _2
$a časopisecké články $7 D016428
700    1_
$a Burša, Filip $u Department of Anesthesiology and Intensive Care Medicine, University Hospital Ostrava, Ostrava, Czech Republic $u Department of Anesthesiology and Intensive Care Medicine, Faculty of Medicine, University of Ostrava, Ostrava, Czech Republic $u Institute of Physiology and Pathophysiology, Faculty of Medicine, University of Ostrava, Ostrava, Czech Republic
700    1_
$a Frelich, Michal $u Department of Anesthesiology and Intensive Care Medicine, University Hospital Ostrava, Ostrava, Czech Republic $u Department of Anesthesiology and Intensive Care Medicine, Faculty of Medicine, University of Ostrava, Ostrava, Czech Republic
700    1_
$a Máca, Jan $u Department of Anesthesiology and Intensive Care Medicine, University Hospital Ostrava, Ostrava, Czech Republic $u Department of Anesthesiology and Intensive Care Medicine, Faculty of Medicine, University of Ostrava, Ostrava, Czech Republic $u Institute of Physiology and Pathophysiology, Faculty of Medicine, University of Ostrava, Ostrava, Czech Republic
700    1_
$a Vodička, Vojtech $u Department of Anesthesiology and Intensive Care Medicine, University Hospital Ostrava, Ostrava, Czech Republic $u Faculty of Medicine, Masaryk University, Brno, Czech Republic
700    1_
$a Straková, Hana $u Department of Anesthesiology and Intensive Care Medicine, University Hospital Ostrava, Ostrava, Czech Republic $u Department of Anesthesiology and Intensive Care Medicine, Faculty of Medicine, University of Ostrava, Ostrava, Czech Republic
700    1_
$a Bílená, Markéta $u Department of Anesthesiology and Intensive Care Medicine, University Hospital Ostrava, Ostrava, Czech Republic $u Department of Anesthesiology and Intensive Care Medicine, Faculty of Medicine, University of Ostrava, Ostrava, Czech Republic
700    1_
$a Romanová, Tereza $u Department of Anesthesiology and Intensive Care Medicine, University Hospital Ostrava, Ostrava, Czech Republic $u Department of Anesthesiology and Intensive Care Medicine, Faculty of Medicine, University of Ostrava, Ostrava, Czech Republic
700    1_
$a Tomášková, Hana $u Department of Epidemiology and Public Health, Faculty of Medicine, University of Ostrava, Ostrava, Czech Republic
773    0_
$w MED00198806 $t Therapeutic advances in respiratory disease $x 1753-4666 $g Roč. 18 (2024), s. 17534666241282590
856    41
$u https://pubmed.ncbi.nlm.nih.gov/39418135 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20250121 $b ABA008
991    __
$a 20250206110002 $b ABA008
999    __
$a ok $b bmc $g 2263744 $s 1240200
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2024 $b 18 $c - $d 17534666241282590 $e - $i 1753-4666 $m Therapeutic advances in respiratory disease $n Ther Adv Respir Dis $x MED00198806
LZP    __
$a Pubmed-20250121

Find record

Citation metrics

Archiving options